Our group has previously identified several biomarkers that can predict adverse limb events in patients with PAD, including fatty acid binding proteins [7,8,9,10,11], inflammatory proteins [12], and Cystatin C [13]; however, the investigation of biomarkers that can predict MACEs in patients with PAD has been limited. This evidence concerns the gene CST3 and peripheral arterial disease.